PE20191236A1 - Compuestos de pirazolopirimidina y metodos de uso de los mismos - Google Patents
Compuestos de pirazolopirimidina y metodos de uso de los mismosInfo
- Publication number
- PE20191236A1 PE20191236A1 PE2019001227A PE2019001227A PE20191236A1 PE 20191236 A1 PE20191236 A1 PE 20191236A1 PE 2019001227 A PE2019001227 A PE 2019001227A PE 2019001227 A PE2019001227 A PE 2019001227A PE 20191236 A1 PE20191236 A1 PE 20191236A1
- Authority
- PE
- Peru
- Prior art keywords
- methods
- cyano
- halogen
- compounds
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Referido a un compuesto de formula general (IA), o una sal farmaceuticamente aceptable, en donde: A es un anillo condensado seleccionado entre el grupo que consiste en un grupo aromatico de 6 miembros, un grupo heterociclico de 5 o 6 miembros, entre otros; R es H, halogeno, ciano, entre otros; R0 es H, halogeno, ciano, alquilo C1-C3, entre otros; R1 es H, alquenilo C2-C6, entre otros. Un compuesto preferido es N-[3-[3-(difluorometoxi)-2-naftil]-1H-pirazol-4-il]pirazolo[1,5-a]pirimidin-3-carboxamida. Estos compuestos son inhibidores de molecula pequena de una Janus cinasa, tal como JAK1. Tambien se refiere a metodos de preparacion de los mismos, sus compuestos intermedios y su uso en el tratamiento de una enfermedad inflamatoria como el asma.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016112932 | 2016-12-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191236A1 true PE20191236A1 (es) | 2019-09-11 |
Family
ID=61094385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001227A PE20191236A1 (es) | 2016-12-29 | 2017-12-22 | Compuestos de pirazolopirimidina y metodos de uso de los mismos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11155557B2 (es) |
| EP (1) | EP3562809B1 (es) |
| JP (1) | JP6900491B2 (es) |
| KR (1) | KR20190100337A (es) |
| CN (1) | CN110114343B (es) |
| AU (1) | AU2017385543A1 (es) |
| BR (1) | BR112019013287A2 (es) |
| CA (1) | CA3046435A1 (es) |
| CL (1) | CL2019001694A1 (es) |
| CO (1) | CO2019006220A2 (es) |
| CR (1) | CR20190310A (es) |
| IL (1) | IL267671A (es) |
| MA (1) | MA47167A (es) |
| MX (1) | MX2019007339A (es) |
| PE (1) | PE20191236A1 (es) |
| PH (1) | PH12019501022A1 (es) |
| RU (1) | RU2019123319A (es) |
| WO (1) | WO2018122212A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017385543A1 (en) | 2016-12-29 | 2019-05-23 | F. Hoffmann-La Roche Ag | Pyrazolopyrimidine compounds and methods of use thereof |
| BR112019024322A2 (pt) | 2017-05-22 | 2020-06-16 | F. Hoffmann-La Roche Ag | Compostos e composições terapêuticos e métodos de uso dos mesmos |
| WO2019139714A1 (en) * | 2018-01-15 | 2019-07-18 | Genentech, Inc. | Pyrazolopyrimidine compounds as jak inhibitors |
| MA56518A (fr) | 2019-06-18 | 2022-04-27 | Hoffmann La Roche | Inhibiteurs de sulfone pyrazolopyrimidine de jak kinases et leurs utilisations |
| WO2020257143A1 (en) * | 2019-06-18 | 2020-12-24 | Genentech, Inc. | Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof |
| CN114026096A (zh) * | 2019-06-18 | 2022-02-08 | 豪夫迈·罗氏有限公司 | 四唑取代的吡唑并嘧啶类jak激酶抑制剂及其用途 |
| WO2022175829A1 (en) * | 2021-02-17 | 2022-08-25 | Cellix Bio Private Limited | Topical formulations and compositions |
| WO2024052512A1 (en) * | 2022-09-09 | 2024-03-14 | Chiesi Farmaceutici S.P.A. | Heterocyclic derivatives as janus kinase inhibitors |
| WO2024052513A1 (en) * | 2022-09-09 | 2024-03-14 | Chiesi Farmaceutici S.P.A. | Heterocyclic derivatives as janus kinase inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| WO1997002289A1 (en) | 1995-07-06 | 1997-01-23 | Zeneca Limited | Peptide inhibitors of fibronectine |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| EP1458682B1 (en) | 2001-12-20 | 2006-08-30 | Bayer HealthCare AG | 1,4-dihydro-1,4-diphenylpyridine derivatives |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| EP2251341A1 (en) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
| MX2010014005A (es) | 2008-06-20 | 2011-02-15 | Genentech Inc | Compuestos de triazolopiridina inhibidores de jak y los metodos. |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| CN106459039A (zh) | 2014-05-23 | 2017-02-22 | 豪夫迈·罗氏有限公司 | 为jak抑制剂的5‑氯‑2‑二氟甲氧基苯基吡唑并嘧啶化合物 |
| TW201720828A (zh) | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| CN108473501B (zh) | 2016-02-18 | 2021-07-16 | 豪夫迈·罗氏有限公司 | 治疗化合物、其组合物及使用方法 |
| JP7208020B2 (ja) | 2016-06-29 | 2023-01-18 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン誘導体、その結合体、及びそれを含む組成物、並びにその治療的用途 |
| AU2017385543A1 (en) | 2016-12-29 | 2019-05-23 | F. Hoffmann-La Roche Ag | Pyrazolopyrimidine compounds and methods of use thereof |
-
2017
- 2017-12-22 AU AU2017385543A patent/AU2017385543A1/en not_active Abandoned
- 2017-12-22 RU RU2019123319A patent/RU2019123319A/ru not_active Application Discontinuation
- 2017-12-22 KR KR1020197022055A patent/KR20190100337A/ko not_active Application Discontinuation
- 2017-12-22 CN CN201780081495.7A patent/CN110114343B/zh active Active
- 2017-12-22 PE PE2019001227A patent/PE20191236A1/es unknown
- 2017-12-22 MA MA047167A patent/MA47167A/fr unknown
- 2017-12-22 WO PCT/EP2017/084569 patent/WO2018122212A1/en unknown
- 2017-12-22 CR CR20190310A patent/CR20190310A/es unknown
- 2017-12-22 JP JP2019535901A patent/JP6900491B2/ja active Active
- 2017-12-22 MX MX2019007339A patent/MX2019007339A/es unknown
- 2017-12-22 CA CA3046435A patent/CA3046435A1/en not_active Abandoned
- 2017-12-22 EP EP17836033.5A patent/EP3562809B1/en active Active
- 2017-12-22 BR BR112019013287A patent/BR112019013287A2/pt not_active Application Discontinuation
-
2019
- 2019-05-08 PH PH12019501022A patent/PH12019501022A1/en unknown
- 2019-06-14 CO CONC2019/0006220A patent/CO2019006220A2/es unknown
- 2019-06-19 CL CL2019001694A patent/CL2019001694A1/es unknown
- 2019-06-25 US US16/452,058 patent/US11155557B2/en active Active
- 2019-06-26 IL IL267671A patent/IL267671A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019007339A (es) | 2019-09-06 |
| CR20190310A (es) | 2019-08-21 |
| KR20190100337A (ko) | 2019-08-28 |
| MA47167A (fr) | 2019-11-06 |
| AU2017385543A1 (en) | 2019-05-23 |
| CA3046435A1 (en) | 2018-07-05 |
| IL267671A (en) | 2019-08-29 |
| EP3562809B1 (en) | 2021-06-09 |
| CO2019006220A2 (es) | 2019-06-28 |
| CL2019001694A1 (es) | 2019-11-22 |
| RU2019123319A (ru) | 2021-02-01 |
| EP3562809A1 (en) | 2019-11-06 |
| CN110114343B (zh) | 2022-09-06 |
| PH12019501022A1 (en) | 2019-12-16 |
| JP6900491B2 (ja) | 2021-07-07 |
| BR112019013287A2 (pt) | 2019-12-24 |
| US11155557B2 (en) | 2021-10-26 |
| RU2019123319A3 (es) | 2021-02-01 |
| WO2018122212A1 (en) | 2018-07-05 |
| US20190345165A1 (en) | 2019-11-14 |
| CN110114343A (zh) | 2019-08-09 |
| JP2020503339A (ja) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191236A1 (es) | Compuestos de pirazolopirimidina y metodos de uso de los mismos | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| PE20190395A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos | |
| PE20170189A1 (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| PE20170663A1 (es) | Compuestos de 5- cloro- 2- difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos | |
| PE20171307A1 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
| PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
| EA202092441A1 (ru) | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 | |
| PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| AR073551A1 (es) | Pirimidinas macrociclicas como inhibidores de proteina cinasa | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| EA201691302A1 (ru) | Новые гетероциклические соединения | |
| PE20210658A1 (es) | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat) | |
| PE20190339A1 (es) | 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 | |
| PE20051089A1 (es) | Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina | |
| PH12020550143A1 (en) | Salts of pyrrolotriazine derivatives useful as tam inhibitors | |
| EA201591804A1 (ru) | Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы | |
| EA201400182A1 (ru) | Производные пиридин-2(1н)-она в качестве ингибиторов jak | |
| CU24608B1 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos | |
| CL2017002059A1 (es) | Compuestos 4- sustitutos de benzoxaborol y uso de los mismos | |
| EA201691934A1 (ru) | Замещенные 4,5,6,7-тетрагидро-пиразоло[1,5-альфа]пиримидиновые производные и 2,3-дигидро-1h-имидазо[1,2-бета]пиразольные производные в качестве ингибиторов ros1 |